Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290355 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL3335410 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL1162330 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL4611332 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL2745700 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL525690 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL2299446 | 0.98 | KDM4E (0.41) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL2193108 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL29118739 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL27837711 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220223-B2 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2019-03-05 | — | — | US | claimed |
| US-20160199274-A1 | COSMETIC COMPOSITION WITH A VOLUMIZING EFFECT | OREAL (FR) | 2016-07-14 | — | — | US | claimed |
| US-9320693-B2 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2016-04-26 | — | — | US | claimed |
| EP-1762216-B1 | COSMETIC PREPARATION | NISSHIN OILLIO GROUP LTD (JP) | 2016-04-20 | — | — | EP | claimed |
| EP-1800650-B2 | Cosmetic composition providing a voluminous effect | OREAL (FR) | 2013-08-14 | — | — | EP | claimed |
| EP-1800649-B2 | Cosmetic composition with volumising effect | OREAL (FR) | 2012-10-10 | — | — | EP | claimed |
| WO-2011101239-A2 | COSMETIC OR DERMATOLOGICAL USES OF A POWDER COMPRISING A FILLER, AN ESSENTIAL OIL AND A HYDROXYLATED ESTER OF POLYOL AND OF C4 TO C16 CARBOXYLIC ACID(S) | L'OREAL (FR) | 2011-08-25 | — | — | WO | claimed |
| EP-1800650-B1 | Cosmetic composition providing a voluminous effect | OREAL (FR) | 2010-11-03 | — | — | EP | claimed |
| EP-2124576-A1 | ESSENTIAL OIL COMPOSITIONS FOR KILLING OR REPELLING ECTOPARASITES AND PESTS AND METHODS FOR USE THEREOF | Nonits LLC (US) | 2009-12-02 | — | — | EP | claimed |
| EP-1800649-B1 | Cosmetic composition with volumising effect | OREAL (FR) | 2008-12-10 | — | — | EP | claimed |
| WO-2008101131-A1 | ESSENTIAL OIL COMPOSITIONS FOR KILLING OR REPELLING ECTOPARASITES AND PESTS AND METHODS FOR USE THEREOF | NONITS LLC (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2008100397-A1 | PERSONAL LUBRICANT COMPOSITIONS THAT ARE FREE OF GLYCERIN AND PARABENS | BIOFILM, IP, LLC (US) | 2008-08-21 | — | — | WO | claimed |
| US-20080193387-A1 | ESSENTIAL OIL COMPOSITIONS FOR KILLING OR REPELLING ECTOPARASITES AND PESTS AND METHODS FOR USE THEREOF | RICKI DE WOLFFE | 2008-08-14 | — | — | US | claimed |
| US-20070196301-A1 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2007-08-23 | — | — | US | claimed |
| US-20070141003-A1 | Cosmetic composition with a volumizing effect | L'OREAL (FR) | 2007-06-21 | — | — | US | claimed |
| US-20250051621-A1 | BIODEGRADABLE RESIN AQUEOUS DISPERSION HAVING EXCELLENT LONG-TERM STORAGE STABILITY AND METHOD FOR USING SAME | MIYOSHI OIL & FAT CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12179977-B2 | Film for food packaging, stretch film for food packaging, film for automatic packaging machine for food packaging, and method for packaging food | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-31 | — | — | US | disclosed |
| US-6440437-B1 | OIL IN WATER EMULSION COMPRISING NATURAL FAT OR OIL, STEROL, HUMECTANT, SURFACTANT, AND WATER; ENHANCES SKIN BARRIER; BABY OR HAND WIPES | KIMBERLY-CLARK WORLDWIDE, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1171094-A1 | WET WIPES HAVING SKIN HEALTH BENEFITS | Kimberly-Clark Worldwide, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000064408-A1 | WET WIPES HAVING SKIN HEALTH BENEFITS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196301-A1 | Cosmetic composition with a volumizing effect | LIPA, CUTA, LIPG | KDM4E 3219/4885DUSP3 4701/4885MEN1 779/4885 |
| US-20070141003-A1 | Cosmetic composition with a volumizing effect | CUTA, ELOVL1, LIPA | KDM4E 2977/4885DUSP3 4778/4885MEN1 492/4885 |
| US-10220223-B2 | Cosmetic composition with a volumizing effect | CUTA, LIPA, LIPG | KDM4E 3255/4885DUSP3 4751/4885MEN1 610/4885 |
| US-20160199274-A1 | COSMETIC COMPOSITION WITH A VOLUMIZING EFFECT | CUTA, LIPA, LIPG | KDM4E 3255/4885DUSP3 4751/4885MEN1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.